Treatment of Acute Gout Flares

First-Line Treatment Options

• The American College of Rheumatology strongly recommends three equally effective first-line agents for acute gout flares: colchicine, NSAIDs, and oral corticosteroids 1, 2
• Colchicine is most effective when initiated within 12 hours of symptom onset, with a maximum dose of 1.8 mg over one hour 3, 4
• NSAIDs should be used at full FDA-approved anti-inflammatory doses, with contraindications including peptic ulcer disease, renal failure, uncontrolled hypertension, and cardiac failure 2, 3, 4
• Oral corticosteroids, such as prednisone 30-35 mg daily for 3-5 days, are particularly effective for flares with significant systemic inflammation and are safer than NSAIDs in patients with renal impairment, cardiovascular disease, or gastrointestinal contraindications 2, 4, 5

Treatment Selection Algorithm

• The single most important factor for treatment success is early initiation, not which agent is chosen 2
• Intra-articular corticosteroid injection is highly effective and preferred for monoarticular or oligoarticular flares (1-2 large joints) 3, 5
• Parenteral glucocorticoids are strongly recommended over IL-1 inhibitors or ACTH for patients unable to take oral medications 1, 2, 5

Special Populations and Situations

• IL-1 inhibitors, such as canakinumab 150 mg subcutaneously, are conditionally recommended for patients with contraindications to all first-line agents and frequent flares 2, 3
• Current infection is an absolute contraindication to IL-1 blockers 3
• Patients already on urate-lowering therapy should continue it during acute flare, as interrupting it can worsen the flare and complicate long-term management 1, 4

Adjunctive Measures

• Topical ice application is conditionally recommended as adjuvant therapy 2

Critical Pitfalls to Avoid

• Delaying treatment initiation is a critical pitfall, as early intervention is the most important determinant of success 2
• Using colchicine in patients with severe renal impairment or on strong CYP3A4/P-glycoprotein inhibitors can result in fatal toxicity 3
• Prescribing NSAIDs in elderly patients with renal impairment, heart failure, or peptic ulcer disease is not recommended 3
• Stopping urate-lowering therapy during acute flare can worsen the flare and complicate long-term management 1, 4

Treatment of Acute Gout Flares

First-Line Treatment Selection

• The American College of Rheumatology recommends oral corticosteroids as the safest option for patients with renal impairment, cardiovascular disease, gastrointestinal contraindications to NSAIDs, uncontrolled hypertension, and heart failure 6

Critical Management Principles

• The American College of Rheumatology recommends continuing urate-lowering therapy during flares and conditionally starting it during the flare with appropriate anti-inflammatory coverage 6

Prophylaxis During Urate-Lowering Therapy Initiation

• The American College of Rheumatology strongly recommends concomitant anti-inflammatory prophylaxis for 3-6 months when initiating urate-lowering therapy to prevent treatment-induced flares 6, 7
• The American College of Rheumatology recommends low-dose colchicine (0.5-0.6 mg once or twice daily) as the first-line prophylaxis 6

Management of Gout Flare

First-Line Treatment

• The American College of Rheumatology strongly recommends low-dose colchicine over high-dose colchicine due to similar efficacy with lower risk of adverse effects 8
• The American College of Rheumatology recommends starting treatment immediately with colchicine, NSAIDs, or oral corticosteroids, as early initiation is the most critical factor for success, not the choice of agent 8

Urate-Lowering Therapy

• The American College of Rheumatology conditionally recommends starting urate-lowering therapy during a gout flare rather than waiting for resolution, with concomitant anti-inflammatory prophylaxis 9
• The American College of Rheumatology strongly recommends concomitant anti-inflammatory prophylaxis when starting urate-lowering therapy, and continuing prophylaxis for 3-6 months 9

Adjunctive Measures

• The American College of Rheumatology conditionally recommends topical ice application as adjuvant therapy 8

Treatment of Acute Gout Flares with Concomitant Medications

Critical Contraindications and Precautions

• The American College of Rheumatology recommends avoiding colchicine in patients with severe renal impairment or those on strong CYP3A4 or P-glycoprotein inhibitors due to the risk of fatal toxicity 10
• The European League Against Rheumatism suggests concomitant anti-inflammatory prophylaxis for 3-6 months when starting urate-lowering therapy to prevent treatment-induced flares 10

Prophylaxis and Urate-Lowering Therapy

• The American College of Rheumatology conditionally recommends starting urate-lowering therapy during the flare with appropriate anti-inflammatory coverage, and continuing it without interruption during the acute flare 10
• The European League Against Rheumatism strongly recommends concomitant anti-inflammatory prophylaxis, such as low-dose colchicine 0.5-0.6 mg once or twice daily, when starting urate-lowering therapy 10

Management of Acute Gout Flare

Urate-Lowering Therapy

• The American College of Rheumatology recommends continuing urate-lowering therapy during an acute gout flare, as stopping it can worsen the flare and complicate long-term management 11
• Urate-lowering therapy can be started during an acute flare with appropriate anti-inflammatory coverage, and concomitant anti-inflammatory prophylaxis is strongly recommended for 3-6 months to prevent treatment-induced flares 11

Adjunctive Measures

• Topical ice application is conditionally recommended as adjuvant therapy, although the citation is not provided, it is generally accepted as a common practice
• However, since there is no citation, this fact will not be included.

Prophylaxis

• The American College of Rheumatology conditionally recommends low-dose colchicine (0.5-0.6 mg once or twice daily), NSAIDs, or prednisone (<10 mg/day) as prophylaxis for 3-6 months when initiating urate-lowering therapy to prevent treatment-induced flares 11

Acute Gout Flare Management

First-Line Treatment

• The American College of Rheumatology recommends starting treatment immediately with one of three equally effective first-line agents: colchicine, full-dose NSAIDs, or oral corticosteroids, with early initiation within 12 hours being the single most critical factor for success 12
• The American College of Rheumatology suggests choosing colchicine as the preferred first-line agent when initiated within 12 hours of symptom onset, using FDA-approved dosing: 1.2 mg immediately, followed by 0.6 mg one hour later 12
• The American College of Rheumatology conditionally recommends IL-1 inhibitors, such as canakinumab 150 mg subcutaneously, only for patients with contraindications to all first-line agents and frequent flares 12

Urate-Lowering Therapy Management

• The American College of Rheumatology recommends continuing urate-lowering therapy without interruption during the acute flare, as stopping it worsens the flare and complicates long-term management, and conditionally starting it during the flare with appropriate anti-inflammatory coverage 12, 13
• The American College of Rheumatology strongly recommends concomitant anti-inflammatory prophylaxis for 3-6 months when starting urate-lowering therapy to prevent treatment-induced flares 13
• The American College of Rheumatology recommends continuing prophylaxis for at least 3-6 months after urate-lowering therapy initiation, with ongoing evaluation and continued prophylaxis as needed if flares persist 13

Adjunctive Measures

• The American College of Rheumatology conditionally recommends topical ice application as adjuvant therapy 12

Lifestyle Modifications

• The American College of Rheumatology recommends limiting alcohol intake, especially beer, to manage acute gout flare 12
• The American College of Rheumatology recommends limiting purine-rich foods, such as organ meats and shellfish, to manage acute gout flare 12
• The American College of Rheumatology recommends limiting high-fructose corn syrup intake to manage acute gout flare 12
• The American College of Rheumatology recommends a weight loss program for overweight or obese patients to manage acute gout flare 12

Evidence‑Based Management of Acute Gout Flare in the Knee

Immediate Pharmacologic Management

• Initiating therapy within the first 12 hours of symptom onset is the single most critical factor for successful resolution of an acute gout flare, independent of the specific first‑line drug chosen. 14
• Colchicine, full‑dose non‑steroidal anti‑inflammatory drugs (e.g., indomethacin or naproxen), and oral prednisone (30–35 mg daily for 3–5 days) have comparable effectiveness for treating an acute gout flare in the knee. 14

Adjunctive Non‑Pharmacologic Measures

• Applying ice to the affected knee provides additional pain relief during an acute gout flare. 14
• High‑dose colchicine regimens (e.g., dosing every hour) are associated with dangerous toxicity and do not confer greater efficacy than low‑dose regimens. 14

Indications for Initiating Long‑Term Uric‑Acid‑Lowering Therapy

• After a first gout attack, long‑term uric‑acid‑lowering medication is generally unnecessary unless the patient has a serum uric‑acid concentration > 9 mg/dL, a history of kidney stones, or chronic kidney disease stage 3 or worse. [15][16]
• Patients experiencing frequent gout flares (≥ 2 per year) should start chronic uric‑acid‑lowering therapy with allopurinol, beginning at ≤ 100 mg/day and titrating upward as needed. 16

Follow‑Up and Monitoring

• Schedule a follow‑up visit within 1–2 weeks after the flare resolves to confirm the diagnosis (potentially with joint‑fluid analysis), re‑measure serum uric‑acid levels, and decide whether preventive therapy is indicated. [15][16]

Acute Gout Attack Management

First‑Line Anti‑Inflammatory Therapy

• Initiate treatment within 12–24 hours of symptom onset; early initiation is more critical than the specific agent chosen, and NSAIDs (full anti‑inflammatory dose), oral prednisone 30–35 mg daily for 3–5 days, or colchicine (1.2 mg then 0.6 mg one hour later, max 1.8 mg) are equally effective. [17][18]

Selection of the Appropriate First‑Line Agent

Oral Corticosteroids

• Prefer oral prednisone 30–35 mg daily for 3–5 days when the patient has heart failure or uncontrolled hypertension, because NSAIDs are contraindicated in these conditions. 17

NSAIDs

• Choose NSAIDs at full FDA‑approved anti‑inflammatory doses only if the patient has no renal impairment, no cardiovascular disease, no gastrointestinal contraindications, and no uncontrolled hypertension. 17

Colchicine

• Use colchicine (1.2 mg then 0.6 mg) when the patient can start therapy within 12 hours of flare onset, has no severe renal impairment, and is not receiving strong CYP3A4 or P‑glycoprotein inhibitors. 17

Continuation of Existing Urate‑Lowering Therapy (ULT)

• Do not discontinue allopurinol or other ULT during an acute gout flare; stopping it worsens the flare and hampers long‑term control. [17][18]

Initiating ULT During an Acute Flare

• ULT may be started during an acute flare provided adequate anti‑inflammatory coverage is given; this is a conditional recommendation. [19][20]
• When initiating allopurinol in this setting, begin with a low dose (≤100 mg/day, lower if chronic kidney disease is present). 20

Anti‑Inflammatory Prophylaxis When Starting ULT

• Provide concomitant anti‑inflammatory prophylaxis for 3–6 months after ULT initiation to prevent treatment‑induced flares; this is a conditional recommendation. [19][20]

Prophylaxis Options

• Low‑dose colchicine (0.5–0.6 mg once or twice daily) – first‑line prophylaxis. [conditional]
• Low‑dose NSAIDs – acceptable alternative. [17][18]
• Low‑dose prednisone (<10 mg/day) – another alternative. [conditional]

Timing of Treatment Initiation

• Delaying anti‑inflammatory therapy beyond 12–24 hours markedly reduces the likelihood of rapid symptom resolution; early treatment is the single most critical factor for success. 17

Dose Adjustments in Chronic Kidney Disease (CKD)

• Colchicine requires dose reduction in patients with CKD; exact adjustment depends on renal function. 17
• Allopurinol should be started at ≤100 mg/day (or lower) in CKD stage ≥3. 20

Acute Gout Flare Management

Immediate Initiation

• Initiate anti‑inflammatory therapy within 12 hours of symptom onset; early treatment is the single most important determinant of rapid pain relief, and oral prednisone, colchicine, or full‑dose NSAIDs are equally effective【21】.

First‑Line Pharmacologic Selection

• Oral prednisone 30–35 mg daily for 5 days is preferred when the patient has severe renal impairment (eGFR < 30 mL/min), cardiovascular disease/heart failure, peptic‑ulcer disease or high GI‑bleed risk, uncontrolled hypertension, or hepatic cirrhosis【21】.
• Colchicine 1.2 mg then 0.6 mg one hour later (maximum 1.8 mg) is appropriate when treatment can start within 12 hours, the patient does not have severe renal impairment, and there are no strong CYP3A4 or P‑glycoprotein inhibitors (e.g., clarithromycin, cyclosporine, ritonavir, ketoconazole)【21】.
• Full‑dose NSAIDs (e.g., naproxen 500 mg BID, indomethacin 50 mg TID) are suitable only if the patient has no renal impairment, no cardiovascular disease or heart failure, no GI contraindications, and no uncontrolled hypertension; a proton‑pump inhibitor should be added when any GI risk factor exists【21】.

Dosing Details

• Prednisone: 0.5 mg/kg/day (≈30–35 mg for average adults). Regimens may be 5–10 days at full dose with abrupt stop for simple monoarticular flares, or 2–5 days at full dose followed by a 7–10 day taper for severe or polyarticular attacks【21】.
• Colchicine: 1.2 mg immediately, then 0.6 mg one hour later (max 1.8 mg). High‑dose hourly regimens are avoided because they increase toxicity without added benefit【21】.
• NSAIDs: Use the FDA‑approved anti‑inflammatory dosing (e.g., naproxen 500 mg BID, indomethacin 50 mg TID)【21】.

Special Populations & Dose Adjustments

• Severe renal impairment (eGFR < 30 mL/min) – avoid NSAIDs; corticosteroids require no dose adjustment; colchicine must be dose‑reduced and is contraindicated in end‑stage renal failure【21】.
• Concurrent strong CYP3A4/P‑gp inhibitors – for gout flare, reduce colchicine to 0.6 mg once then 0.3 mg one hour later (no repeat dosing for 3 days); for prophylaxis, use 0.3 mg once daily; colchicine is absolutely contraindicated if severe renal or hepatic impairment co‑exists【21】.

Management of Urate‑Lowering Therapy (ULT) During Flare

• Do not discontinue existing ULT (allopurinol, febuxostat) during an acute flare, as stopping worsens the attack and hampers long‑term control【21】.
• Initiating ULT during a flare is permissible if adequate anti‑inflammatory coverage is provided (conditional recommendation)【21】.
• When starting ULT, prescribe anti‑inflammatory prophylaxis for 3–6 months:
  
  • First‑line: low‑dose colchicine 0.5–0.6 mg once or twice daily【21】.
  • Second‑line: low‑dose NSAIDs or prednisone < 10 mg/day【21】.
  • Prednisone > 10 mg/day should never be used for prophylaxis because it raises adverse‑event risk without added benefit【21】.

IL‑1 Inhibitor Use

• Canakinumab 150 mg subcutaneously is reserved for patients who cannot use any first‑line agents (colchicine, NSAIDs, corticosteroids), have frequent flares despite optimal management, and have no active infection (absolute contraindication)【21】.

Key Pitfalls to Avoid

• Delaying therapy beyond 12–24 hours markedly reduces treatment success【21】.
• Administering colchicine in severe renal impairment or with strong CYP3A4/P‑gp inhibitors can cause fatal toxicity【21】.
• High‑dose hourly colchicine regimens cause severe gastrointestinal toxicity without improving efficacy【21】.
• Using prednisone > 10 mg/day for flare prophylaxis increases adverse effects without benefit【21】.